Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
特拉替尼（BAY 57-9352）治疗晚期实体瘤患者的 I 期剂量递增研究
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6604724
Strumberg D, Schultheis B, Adamietz I A, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen M E, Mross K
